Neurologist David Geldmacher, M.D., is launching a new clinical effort to prepare a personalized dementia risk assessment for people concerned about their risk for developing memory problems as they age.
Anthony Nicholas, M.D., associate professor in the Department of Neurology, is a co-editor of the first textbook on the subject of protein deimination in human health and disease.
New drugs to slow or even prevent Parkinson’s could be in human studies as early as 2015.
David Geldmacher, M.D., an expert on Alzheimer’s diagnosis and management, shares his latest research and reveals some common myths about the disease.
UAB’s Epilepsy Center is housed in the Department of Neurology under the direction of Jerzy Szaflarski, M.D., Ph.D.
UAB has teamed with the Michael J. Fox Foundation to look for genetic biomarkers for Parkinson’s disease.
Researchers show that high-intensity strength training improves mobility, mood and overall quality of life for Parkinson’s patients.
Erik Roberson, M.D., Ph.D., and Andrew West, Ph.D., have been named co-directors of the Center for Neurodegeneration and Experimental Therapeutics.
Gel form of a medication for Parkinson’s disease speeds response time over traditional pills.
Scott Plutchak's diagnosis of transverse myelitis exposed him to a quality of medical communication not often encountered.